Taken together, these data suggest that in patients with PKU, inhibition of SLC6A19 may effect a higher degree of urinary Phe excretion than that observed in healthy volunteers, providing a stronger drive to lower the pathologically elevated levels of this amino acid in blood. Here, SLC6A19 is linked to phenylketonuria.